Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social DisparitiesBusiness Wire • 11/30/21
Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral TherapiesBusiness Wire • 11/23/21
Takeda's Area Offices in Dubai, United Arab Emirates Certified Sustainable and InauguratedGlobeNewsWire • 11/16/21
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare DiseaseBusiness Wire • 11/04/21
5 Big Dividend Biotech and Pharmaceutical Stocks Have Strong Upside Potential24/7 Wall Street • 11/01/21
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 10/29/21
Takeda Pharmaceutical: Diversify Your Book With This Excellent Japanese Pharma PlaySeeking Alpha • 10/28/21
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global BrandsBusiness Wire • 10/28/21
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid TumorsBusiness Wire • 10/27/21
Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900MGeekWire • 10/14/21
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into MassachusettsBusiness Wire • 10/13/21
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without ResistanceBusiness Wire • 10/07/21